Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion type Assertion NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_head.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion description "[Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_provenance.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion evidence source_evidence_literature NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_provenance.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion SIO_000772 21987462 NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_provenance.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion wasDerivedFrom befree-2016 NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_provenance.
- NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_assertion wasGeneratedBy ECO_0000203 NP930025.RASWhq3GVR_-I1O-L6lUKdaswZr58Op9NX00-OssnwHVw130_provenance.